Zydus gets approval to conduct Phase II clinical study in patients with CAPS in Australia
Drug firm Zydus Cadila on Monday said it has received approval to commence Phase II clinical study of its upcoming product with patients suffering with Cryopyrin-Associated Periodic Syndrome (CAPS) in Australia.
The clinical trial in Australia will study the safety, tolerability, pharmacokinetics, among others. Image for representational purpose only. Source: Reuters